ABL1 and acute myeloid leukemia: Dasatinib, as a potent BCR-ABL inhibitor, is resistant/intolerant to imatinib and has been studied in combination with multiple chemotherapy regimens in AML patients aged 13–15 years (Foà et al., 2011; Kivioja et al., 2019; Welch, 2020).